Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study. (15th October 2020)

• Record Type: Journal Article
• Authors: Marchesini, Gessica; Nadali, Gianpaolo; Facchinelli, Davide; Candoni, Anna; Cattaneo, Chiara; Laurenti, Luca; Fanci, Rosa; Farina, Francesca; Lessi, Federica; Visentin, Andrea; Marchesi, Francesco; Prezioso, Lucia; Spolzino, Angelica; Tisi, Maria Chiara; Trastulli, Fabio; Picardi, Marika; Verga, Luisa; Dargenio, Michelina; Busca, Alessandro; Pagano, Livio
• Is Part Of: British journal of haematology. Volume 193:Number 2(2021)
• Page Start: 316
• Page End: 324
• Publication Date: 2020-10-15
• Subjects: infections -- lymphoproliferative diseases -- targeted therapy; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.17145
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: We describe the opportunistic infections occurring in 362 patients with lymphoproliferative disorders treated with ibrutinib and idelalisib in clinical practice. Overall, 108 of 362 patients (29·8%) developed infections, for a total of 152 events. Clinically defined infections (CDI) were 49·3% (75/152) and microbiologically defined infections (MDI) were 50·7% (77/152). Among 250 patients treated with ibrutinib, 28·8% (72/250) experienced one or more infections, for a total of 104 episodes. MDI were 49% (51/104). Bacterial infections were 66·7% (34/51), viral 19·6% (10/51) and invasive fungal diseases (IFD) 13·7% (7/51). Among the 112 patients treated with idelalisib, 32·1% (36/112) experienced one or more infections, for a total of 48 episodes. MDI were 54·2% (26/48). Bacterial infections were 34·6% (9/26), viral 61·5% (16/26) and IFD 3·8% (1/26). With ibrutinib, the rate of bacterial infections was significantly higher compared to idelalisib (66·7% vs. 34·6%; P = 0·007), while viral infections were most frequent in idelalisib (61·5% vs. 19·6%; P < 0·001). Although a higher rate of IFD was observed in patients treated with ibrutinib, the difference was not statistically significant (13·7% vs. 3·8% respectively; P = 0·18). Bacteria are the most frequent infections with ibrutinib, while viruses are most frequently involved with idelalisib.